1.Uslan, DZ et al. (2007) Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Archives of Internal Medicine 167, 834–839.
2.Laupland, KB et al. (2004) Severe bloodstream infections: a population-based assessment. Critical Care Medicine 32, 992–997.
3.Khatib, R et al. (2009) Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scandinavian Journal of Infectious Diseases 41, 4–9.
4.van Hal, SJ et al. (2012) Predictors of mortality in Staphylococcus aureus bacteremia. Clinical Microbiology Reviews 25, 362–386.
5.David, MZ and Daum, RS (2010) Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clinical Microbiology Reviews 23, 616–687.
6.Song, JH et al. (2011) Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. Journal of Antimicrobial Chemotherapy 66, 1061–1069.
7.Brady, JM et al. (2007) Sporadic “transitional” community-associated methicillin-resistant Staphylococcus aureus strains from health care facilities in the United States. Journal of Clinical Microbiology 45, 2654–2661.
8.Cho, SY and Chung, DR. (2017) Infection prevention strategy in hospitals in the era of community-associated methicillin-resistant Staphylococcus aureus in the Asia-Pacific region: a review. Clinical Infectious Diseases; 64(Suppl. 2), S82–S90.
9.Wi, YM et al. (2012) High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. International Journal of Antimicrobial Agents 40, 108–113.
10.Paul, M et al. (2010) Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 65, 2658–2665.
11.Kim, SH et al. (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrobial Agents and Chemotherapy 52, 192–197.
12.Chalmers, JD et al. (2014) Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clinical Infectious Diseases 58, 330–339.
13.Aliberti, S et al. (2016) Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases 16, 1364–1376.
14.Forster, AJ et al. (2013) Patient-level factors associated with methicillin-resistant Staphylococcus aureus carriage at hospital admission: a systematic review. American Journal of Infection Control 41, 214–220.
15.CLSI (2010) Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Wayne, PA: Clinical and Labortory Stanadards Institute.
16.Li, JS et al. (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical Infectious Diseases 30, 633–638.
17.Friedman, ND et al. (2002) Health care – associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of Internal Medicine 137, 791–797.
18.McCabe, WR (1974) Gram-negative bacteremia. Advances in Internal Medicine 19, 135–158.
19.Paterson, DL et al. (2004) Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clinical Infectious Diseases 39, 31–37.
20.David, MZ et al. (2011) Methicillin-susceptible Staphylococcus aureus as a predominantly healthcare-associated pathogen: a possible reversal of roles? PLoS One 6, e18217.
21.Miller, LG et al. (2007) Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clinical Infectious Diseases 44, 471–482.
22.McCarthy, NL et al. (2010) Risk factors associated with methicillin resistance among Staphylococcus aureus infections in veterans. Infection Control and Hospital Epidemiology 31, 36–41.
23.Jimenez, JN et al. (2013) A comparison of methicillin-resistant and methicillin-susceptible Staphylococcus aureus reveals no clinical and epidemiological but molecular differences. International Journal of Medical Microbiology 303, 76–83.
24.Arias-Ortiz, PM et al. (2016) Risk factors for methicillin-resistant Staphylococcus aureus bacteremia: a multicenter matched case-control study. Biomedica: Revista del Instituto Nacional de Salud 36, 612–619.
25.Lowy, FD (1998) Staphylococcus aureus infections. New England Journal of Medicine 339, 520–532.
26.Brumfitt, W and Hamilton-Miller, J (1989) Methicillin-resistant Staphylococcus aureus. New England Journal of Medicine 320, 1188–1196.
27.Kaplan, SL et al. (2005) Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clinical Infectious Diseases 40, 1785–1791.
28.Fridkin, SK et al. (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. New England Journal of Medicine 352, 1436–1444.
29.Lee, JY et al. (2014) Bone and joint infection as a predictor of community-acquired methicillin-resistant Staphylococcus aureus bacteraemia: a comparative cohort study. Journal of Antimicrobial Chemotherapy 69, 1966–1971.
30.Yilmaz, M et al. (2016) Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study. Annals of Clinical Microbiology and Antimicrobials 15, 7.
31.Cosgrove, SE et al. (2005) The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infection Control and Hospital Epidemiology 26, 166–174.
32.Blot, SI et al. (2002) Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Archives of Internal Medicine 162, 2229–2235.
33.Mylotte, JM and Tayara, A (2000) Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clinical Infectious Diseases 31, 1170–1174.
34.Castillo, JS et al. (2012) Mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia: a multicenter cohort study in Colombia. Revista Panamericana de Salud Publica 32, 343–350.
35.Yaw, LK, Robinson, JO and Ho, KM (2014) A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. Lancet Infectious Diseases 14, 967–975.
36.Cosgrove, SE et al. (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clinical Infectious Diseases 36, 53–59.
37.Lodise, TP and McKinnon, PS (2005) Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease 52, 113–122.
38.Reed, SD et al. (2005) Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infection Control and Hospital Epidemiology 26, 175–183.
39.Gasch, O et al. (2013) Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clinical Microbiology and infection 19, 1049–1057.
40.Gasch, O et al. (2013) Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 68, 1423–1430.
41.Marchaim, D et al. (2010) Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clinical Microbiology and Infection 16, 747–752.
42.Lodise, TP et al. (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clinical Infectious Diseases 36, 1418–1423.
43.Kim, SH et al. (2004) Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 54, 489–497.
44.Khatib, R et al. (2006) Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. European Journal of Clinical Microbiology & Infectious Diseases 25, 181–185.
45.Fang, CT et al. (2006) Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. Journal of Antimicrobial Chemotherapy 57, 511–519.
46.Yoon, YK et al. (2016) Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis. BMC Infectious Diseases 16, 331.
47.Miller, CE et al. (2012) An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clinical Infectious Diseases 54, 591–600.
48.Holmes, NE et al. (2014) Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates. Journal of Clinical Microbiology 52, 3384–3393.
49.Fowler, VG Jr. et al. (2007) Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. Journal of Infectious Diseases 196, 738–747.
50.Park, KH et al. (2015) Community-associated MRSA strain ST72-SCCmecIV causing bloodstream infections: clinical outcomes and bacterial virulence factors. Journal of Antimicrobial Chemotherapy 70, 1185–1192.